Immix Biopharma (IMMX) Common Equity (2020 - 2026)

Immix Biopharma (IMMX) has 7 years of Common Equity data on file, last reported at $84.4 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 779.38% year-over-year to $84.4 million; the trailing twelve-month figure through Mar 2026 stood at $84.4 million (up 779.38% YoY), and the FY2025 full-year result was $93.8 million, up 607.83% from the prior year.
• Common Equity retreated to $84.4 million in Q1 2026, from $93.8 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $93.8 million in Q4 2025 to a low of $4.7 million in Q2 2025.
• A 5-year average of $24.2 million and a median of $16.7 million in 2022 frame the typical range for Common Equity.
• Across the five-year window, Common Equity slumped 80.52% in 2025 and jumped 779.38% in 2026, its largest moves.
• Tracing IMMX's Common Equity over 5 years: stood at $13.2 million in 2022, then gained by 23.13% to $16.2 million in 2023, then fell by 18.22% to $13.3 million in 2024, then jumped by 607.83% to $93.8 million in 2025, then decreased by 10.06% to $84.4 million in 2026.
• Business Quant data shows IMMX's Common Equity at $84.4 million in Q1 2026, $93.8 million in Q4 2025, and $8.3 million in Q3 2025.